Research and Development
Failure for BMS’ Opdivo in lung cancer trial
October 10, 2016 Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq
Roche’s lung cancer success spells competition for BMS’ Opdivo
October 10, 2016 Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq
“Incorrect classification” of EpiPen leads to $1 billion bill for US government
October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, Heather Bresch, Misclassification, Mylan, Price hike, classification, epipen, price, scandal
Teva to sell Allergan’s UK & Ireland generics business for $770m
October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva
Alnylam’s shares plunge by 42% after deaths in clinical trials
October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran
Novartis axes 175 jobs globally in operations reshuffle
October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Merck’s Keytruda suffers rejection at hands of NICE
October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda
AZ “disappointment” at heart drug failure
October 5, 2016 Research and Development AZ, AstraZeneca, trial failure
FDA warns that certain hepatitis C drugs can have serious side-effects
October 5, 2016 Medical Communications, Research and Development FDA, hepatitis B, hepatitis C
Mylan’s promised half-price EpiPen not available until year’s end
October 5, 2016 Research and Development, Sales and Marketing Mylan, epipen
Roche granted breakthrough therapy designation by FDA
October 5, 2016 Research and Development Actemra, FDA, Giant Cell arteritis, Roche, breakthrough therapy
Patients’ insulin pumps are revealed to be hackable by J&J
October 4, 2016 Research and Development, Sales and Marketing FDA, Hackers, Johnson & Johnson, diabetes, insulin
NICE and the CDF: Are they still up to scratch?
October 4, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE
$600m acquisition bolsters Celgene’s blood cancer portfolio
October 3, 2016 Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma
J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial
October 3, 2016 Research and Development, Sales and Marketing AbbVie, Humira, Johnson & Johnson, guselkumab
